Trial Profile
Phase III trial of VM202 in the patient with critical limb ischemia (CLI).
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2019
Price :
$35
*
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Peripheral arterial disorders; Peripheral ischaemia
- Focus Therapeutic Use
- 17 Nov 2017 New trial record
- 12 Nov 2017 According to a ViroMed media release, IND has been approved by the China Food and Drug Administration.